Prosecution Insights
Prosecution Insights
48 pending office actions • 27 art units • 44 examiners • 0 of 48 (0%) have an AI response strategy ready • 56 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 16 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 16 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (6%) |
| §103 only | 13 (27%) |
| §102 only | 2 (4%) |
| §112 only | 11 (23%) |
| Double-patenting only | 1 (2%) |
| Double-patenting + other | 6 (12%) |
| Multi-statute (no §101) | 12 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRIZER, CASSANDRA SENN | 3 | 60.0% | +26.7% |
| GILL, RACHEL B | 2 | 65.4% | +28.0% |
| RAMIREZ, DELIA M | 2 | 65.1% | +56.3% |
| CLARKE, TRENT R | 1 | 41.1% | +25.3% |
| COLEMAN, BRENDA LIBBY | 1 | 74.6% | +15.6% |
| JOHNSON, KARA D | 1 | 69.1% | +24.6% |
| HILL, MYRON G | 1 | 66.2% | +20.3% |
| JACKSON-TONGUE, LAKIA J | 1 | 68.8% | +20.8% |
| MCKOY, QUINCY ANDRE | 1 | 70.3% | +39.6% |
| BELYAVSKYI, MICHAIL A | 1 | 64.1% | +27.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18266455 | COMPOSITIONS AND METHODS FOR TREATING CANCER | BENAVIDES, JENNIFER ANN | 52d overdue |
| 18283516 | IMMUNOGENIC COMPOSITIONS | GRIZER, CASSANDRA SENN | 26d overdue |
| 18053308 | ANTISENSE THERAPEUTICS FOR BETACORONAVIRUS TREATMENT | BEANE, RANDALL L | 10d overdue |
| 17632783 | CANCER DETECTION AND CLASSIFICATION | BUCHANAN, BAILEY CHEYENNE | 8d overdue |
| 17604227 | Compositions and Methods of Manufacturing Star Polymers for Ligand Display and/or Drug Delivery | KAMM, JUDITH MARIE | 1d overdue |
| 17923394 | ABERRANT POST-TRANSLATIONAL MODIFICATIONS (PTMS) IN METHYL- AND PROPIONIC ACIDEMIA AND A MUTANT SIRTUIN (SIRT) TO METABOLIZE PTMS | BOWLES, DAVID PAUL | 13d |
| 18271901 | REPLICATION-COMPETENT ADENOVIRUS TYPE 4 SARS-COV-2 VACCINES AND THEIR USE | GRIZER, CASSANDRA SENN | 34d |
| 18036112 | ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN | ZAHORIK, AMANDA MARY | 36d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283516 | IMMUNOGENIC COMPOSITIONS | GRIZER, CASSANDRA SENN | 26d overdue |
| 16450852 | NOVEL CRISPR ENZYMES AND SYSTEMS | RAMIREZ, DELIA M | 9d |
| 18271901 | REPLICATION-COMPETENT ADENOVIRUS TYPE 4 SARS-COV-2 VACCINES AND THEIR USE | GRIZER, CASSANDRA SENN | 34d |
| 19289498 | SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS | CLARKE, TRENT R | — |
| 18851859 | SYNTHESIS OF DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS | COLEMAN, BRENDA LIBBY | — |
| 18547037 | FUNCTIONAL BRAIN REGION-SPECIFIC NEURAL SPHEROIDS AND METHODS OF USE | JOHNSON, KARA D | — |
| 18799179 | CHIMERIC VECTORS | HILL, MYRON G | — |
| 18664031 | BRACHYURY DELETION MUTANTS, NON-YEAST VECTORS ENCODING BRACHYURY DELETION MUTANTS, AND THEIR USE | JACKSON-TONGUE, LAKIA J | — |
| Art Unit | Apps |
|---|---|
| 1672 | 4 |
| 1654 | 3 |
| 1624 | 2 |
| 1632 | 2 |
| 1626 | 2 |
| 1644 | 2 |
| 1636 | 2 |
| 1635 | 2 |
| 1682 | 2 |
| 1699 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19289498 | SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS | CLARKE, TRENT R | 1651 | §102§103§112 | Final Rejection | — | Pending | Aug 04, 2025 |
| 18851859 | SYNTHESIS OF DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS | COLEMAN, BRENDA LIBBY | 1624 | §102 | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18547037 | FUNCTIONAL BRAIN REGION-SPECIFIC NEURAL SPHEROIDS AND METHODS OF USE | JOHNSON, KARA D | 1632 | §102§103 | Non-Final OA | — | Pending | Aug 18, 2023 |
| 18799179 | CHIMERIC VECTORS | HILL, MYRON G | — | DP | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18664031 | BRACHYURY DELETION MUTANTS, NON-YEAST VECTORS ENCODING BRACHYURY DELETION MUTANTS, AND THEIR USE | JACKSON-TONGUE, LAKIA J | 1645 | §112DP | Non-Final OA | — | Pending | May 14, 2024 |
| 18694167 | COMPOSITIONS FOR THE TREATMENT OF FOOD AND CHEMICAL ADDICTION AND METHODS OF MAKING AND USING SAME | MCKOY, QUINCY ANDRE | 1626 | §112 | Non-Final OA | — | Pending | Mar 21, 2024 |
| 18583139 | T CELL RECEPTORS RECOGNIZING MUTATED P53 | BELYAVSKYI, MICHAIL A | 1644 | §112Other | Non-Final OA | — | Pending | Feb 21, 2024 |
| 18283516 | IMMUNOGENIC COMPOSITIONS | GRIZER, CASSANDRA SENN | 1672 | §102§103§112 | Final Rejection | 26d overdue | Pending | Sep 22, 2023 |
| 18266455 | COMPOSITIONS AND METHODS FOR TREATING CANCER | BENAVIDES, JENNIFER ANN | 1675 | §102§103§112 | Final Rejection | 52d overdue | Pending | Jun 09, 2023 |
| 18036112 | ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN | ZAHORIK, AMANDA MARY | 1636 | §101§102§103 | Non-Final OA | 36d | Pending | May 09, 2023 |
| 18056356 | GENE THERAPY FOR COMBINED METHYLMALONIC ACIDEMIA/ACIDURIA AND HYPERHOMOCYSTEINEMIA/HOMOCYSTINURIA, COBALAMIN C TYPE, AND DEFICIENCY OF MMACHC | SHIN, DANA H | 1635 | §112 | Final Rejection | 78d | Pending | Nov 17, 2022 |
| 17793089 | ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS AND THEIR USE IN HYPERPOLARIZED IMAGING | DONOHUE, SEAN R | 1618 | §103 | Non-Final OA | 43d | Pending | Jul 15, 2022 |
| 17638139 | COMPOSITIONS INCLUDING IGG FC MUTATIONS AND USES THEREOF | CUNNINGCHEN, KATHLEEN MARY | 1646 | §102§103 | Non-Final OA | — | Pending | Feb 24, 2022 |
| 17632783 | CANCER DETECTION AND CLASSIFICATION | BUCHANAN, BAILEY CHEYENNE | 1682 | §101§102§103 | Final Rejection | 8d overdue | Pending | Feb 03, 2022 |
| 17604227 | Compositions and Methods of Manufacturing Star Polymers for Ligand Display and/or Drug Delivery | KAMM, JUDITH MARIE | 1611 | §103§112Other | Final Rejection | 1d overdue | Pending | Oct 15, 2021 |
| 17478615 | MODIFIED CELLS AND METHODS OF THERAPY | WEHBE, ANNE MARIE SABRINA | 1634 | §103 | Final Rejection | 28d | Pending | Sep 17, 2021 |
| 17214436 | IMMUNORESPONSIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF | MEYERING, SHABANA SHABBEER | 1635 | §103 | Final Rejection | 56d overdue | Pending | Mar 26, 2021 |
| 17274564 | METHODS FOR DECREASING INFLUENZA-INDUCED LETHALITY USING GASTRIN-RELEASING PEPTIDE (GRP) INHIBITORS OR GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) ANTAGONISTS | GAO, ASHLEY HARTMAN | 1678 | §103 | Final Rejection | — | Pending | Mar 09, 2021 |
| 18718766 | BACTERIOPHAGE LAMBDA-VACCINE SYSTEM | GILL, RACHEL B | — | §112 | Non-Final OA | — | Pending | Jun 11, 2024 |
| 18704211 | SINGLE DOMAIN ANTIBODIES TARGETING THE S2 SUBUNIT OF SARS-COV-2 SPIKE PROTEIN | ZOU, NIANXIANG | — | §112 | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18688126 | MIXED LINEAGE KINASE INHIBITORS AND METHODS OF USE | GONZALEZ, LUISALBERTO | 1624 | §103 | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18681019 | HIV-1 VACCINATION AND SAMT-247 MICROBICIDE TO PREVENT HIV-1 INFECTION | GILL, RACHEL B | — | §103§112DP | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18410773 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | MCCAIG, BRIAN A | — | §102§112 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18568738 | COMPOUNDS THAT BIND NON-CANONICAL G-QUADRUPLEX STRUCTURES AND METHODS OF MAKING AND USING THE SAME | FETTEROLF, BRANDON J | 1626 | §102 | Final Rejection | 16d | Pending | Dec 08, 2023 |
| 18562806 | METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS | BERTOGLIO, VALARIE E | 1632 | §112DP | Non-Final OA | — | Pending | Nov 20, 2023 |
| 18290396 | BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS | PYLA, EVELYN Y | 1633 | §103 | Non-Final OA | — | Pending | Nov 13, 2023 |
| 18557396 | PREFUSION-STABILIZED LASSA VIRUS GLYCOPROTEIN COMPLEX AND ITS USE | CORNELIUS, CLAIRE ADRIENNE | 1672 | §112 | Non-Final OA | — | Pending | Oct 26, 2023 |
| 18555137 | RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING SARS-COV-2 SPIKE PROTEIN AND ITS USE | GRIZER, CASSANDRA SENN | 1672 | §103§112 | Non-Final OA | — | Pending | Oct 12, 2023 |
| 18235285 | PRE-EXPOSURE PROPHYLAXIS OF HIV INFECTIONS | JARRELL, NOBLE E | 1699 | §112DP | Non-Final OA | — | Pending | Aug 17, 2023 |
| 18271901 | REPLICATION-COMPETENT ADENOVIRUS TYPE 4 SARS-COV-2 VACCINES AND THEIR USE | GRIZER, CASSANDRA SENN | 1672 | §103§112 | Non-Final OA | 34d | Pending | Jul 12, 2023 |
| 18032132 | HIGH CONCENTRATION METHYLCOBALAMIN OR COMBINATION OF METHYL- AND HYDROXY-COBALAMIN FOR THE TREATMENT OF COBALAMIN C DEFICIENCY DISORDERS | CRAIGO, BAHAR ALAWI | 1699 | §103 | Final Rejection | 44d overdue | Pending | Apr 14, 2023 |
| 18053308 | ANTISENSE THERAPEUTICS FOR BETACORONAVIRUS TREATMENT | BEANE, RANDALL L | 1654 | §102§103§112Other | Non-Final OA | 10d overdue | Pending | Nov 07, 2022 |
| 17923394 | ABERRANT POST-TRANSLATIONAL MODIFICATIONS (PTMS) IN METHYL- AND PROPIONIC ACIDEMIA AND A MUTANT SIRTUIN (SIRT) TO METABOLIZE PTMS | BOWLES, DAVID PAUL | 1654 | §101§102§103§112 | Non-Final OA | 13d | Pending | Nov 04, 2022 |
| 17568298 | COMPOSITIONS AND METHODS FOR REPELLING AND KILLING TICKS AND DETACHMENT OF FEEDING TICKS | BAUER, NICOLA MARIA | 1621 | §103DP | Final Rejection | — | Pending | Jan 04, 2022 |
| 18705869 | USE OF CARBOXYPEPTIDASE E/NEUROTROPHIC FACTOR-ALPHA1 TO TREAT NEURODEGENERATIVE DISEASE | BARRON, SEAN C | 1653 | §103 | Non-Final OA | — | Pending | Apr 29, 2024 |
| 18262779 | Imidazo[1,2- a]pyrazine and Imidazo[1,2- a]pyridine Based Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors | SEITZ, ANTHONY JOSEPH | 1629 | §102§103§112 | Non-Final OA | — | Pending | Jul 25, 2023 |
| 18346680 | CANCER TREATMENT UTILIZING PRE-EXISTING MICROBIAL IMMUNITY | DUNN, LINDSAY MICHELLE | 1644 | §112 | Non-Final OA | — | Pending | Jul 03, 2023 |
| 18627191 | COMPOUNDS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE | OLSON, ANDREA STEFFEL | — | §102§103 | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18697168 | NUCLEAR MAGNETIC RESONANCE METHODS OF DETERMINING HOMEOSTATIC PERTURBATIONS | XU, XIAOYUN | — | §103 | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18277921 | NOVEL COMPOSITIONS OF MATTER COMPRISING STABILIZED CORONAVIRUS ANTIGENS AND THEIR USE | SIFFORD, JEFFREY MARK | 1671 | §112 | Non-Final OA | — | Pending | Aug 18, 2023 |
| 18042743 | METHODS TO PRODUCE VERY LONG CHAIN FATTY ACIDS (VLCFA) | DAVIS, BRIAN J | 1614 | §112 | Non-Final OA | 187d overdue | Pending | Feb 23, 2023 |
| 18572462 | SHORT APOC-II MIMETIC PEPTIDES AND METHODS OF USE | DABKOWSKI, ERINNE R | 1654 | §103§112DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18287630 | HUMAN INSULIN C-ALPHA-PEPTIDES AND METHODS OF USE | LEE, JIA-HAI | 1658 | §103 | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18036392 | SINGLE-CELL PROFILING OF CHROMATIN OCCUPANCY AND RNA SEQUENCING | GRAY, JESSICA | 1682 | §103 | Final Rejection | — | Pending | May 10, 2023 |
| 17904573 | METHODS AND SYSTEMS FOR PREDICTING RATES OF PROGRESSION OF AGE-RELATED MACULAR DEGENERATION | WOITACH, JOSEPH T | 1687 | §103 | Final Rejection | — | Pending | Aug 18, 2022 |
| 16450852 | NOVEL CRISPR ENZYMES AND SYSTEMS | RAMIREZ, DELIA M | 1652 | §112 | Non-Final OA | 9d | Pending | Jun 24, 2019 |
| 16450699 | NOVEL CRISPR ENZYMES AND SYSTEMS | RAMIREZ, DELIA M | 1652 | §112 | Final Rejection | — | Pending | Jun 24, 2019 |
| 17277397 | COMPOSITIONS AND METHODS FOR MODULATION OF LMNA EXPRESSION | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103 | Final Rejection | — | Pending | Mar 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial